Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1918 in Hyperlipidemia
NCT06471218Phase 2Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SHR-1918 in hyperlipidemia (3 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Percent change in calculated LDL-C from baseline to week 24. Started Jul 2024; status: completed.
02
Drugs
SHR-1918
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06471218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06471218.